Denali Therapeutics, a biopharmaceutical company based in South San Francisco, develops therapies for neurodegenerative diseases, with seven clinical candidates and ongoing studies for conditions like ALS and Parkinson's disease. The company went public on December 8, 2017, and has 375 employees.
DNLI filed a patent for "compounds, compositions, and methods" on Wed, September 6, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
